Annexon, Inc. ANNX
Annexon, Inc. (Nasdaq: ANNX) is a CNS/neurology/psychiatry drug developer. Its lead program, tanruprubart (ANX005), is in Phase 3 for Guillain-Barre Syndrome (GBS). Its next catalyst on record is vonaprument: ARCHER II Phase 3 Month 15 primary endpoint readout (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: vonaprument — ARCHER II Phase 3 Month 15 primary endpoint readout (Q4 2026). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| tanruprubart | Guillain-Barre Syndrome | antibody | Phase 3 |
| vonaprument | Geographic atrophy (dry AMD) | antibody | Phase 3 |
| ANX1502 | Cold agglutinin disease (autoimmune) | small molecule | Phase 1 |
Recent results and decisions
- Aug 6, 2026positive First 10 US/EU patients in open-label FORWARD study: all showed clinically meaningful muscle-strength improvement within four days of a single 30 mg/kg infusion; the one ventilated patient came off the ventilator within four days.
All patients treated in the study showed rapid, clinically meaningful improvement in muscle strength within four days.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 CNS/neurology/psychiatry companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.